Stephen Broderick

Papers

Total Citations

299

H-Index

About

Dr. Stephen Broderick is a leading thoracic surgeon and translational researcher whose work is reshaping the surgical management of lung cancer. His primary research focuses on the intersection of immunotherapy and thoracic oncology, particularly the integration of neoadjuvant checkpoint inhibitors into the treatment paradigm for resectable non–small cell lung cancer (NSCLC). His landmark 2018 study, "Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer," has garnered nearly 300 citations, establishing a foundational proof-of-concept that preoperative immunotherapy is both safe and feasible. This work demonstrated major pathological responses in a subset of patients, directly influencing subsequent clinical trials and shifting practice toward earlier immune-based interventions. Beyond this, Dr. Broderick has contributed extensively to optimizing surgical techniques and perioperative outcomes, with a focus on minimally invasive approaches and enhanced recovery protocols. His research consistently bridges the gap between cutting-edge oncology and practical surgical care, making him a pivotal figure in the evolution of multidisciplinary lung cancer treatment.